Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of XM 02 vs Filgrastim in Lung Cancer Patients Receiving Platinum-Based Chemotherapy
2004-001450-84Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- Aug 2004
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tbo-filgrastim in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and neutropenia (2 arms), sponsored by BioGeneriX AG. Primary endpoints: Safety of XM 02 over up to six chemotherapy cycles and Efficacy of XM 02 vs filgrastim during the first chemotherapy cycle. Started Aug 2004; status: completed.
02
Drugs
tbo-filgrastim
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)neutropenia
Beyond the preview
Go deeper on 2004-001450-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001450-84.